Protein Degrader PROTAC Patents

Targeted protein degradation (TPD) patents cover PROTAC bifunctional-degrader innovations; molecular-glue innovations; E3-ligase-ligand and recruitment innovations; and ternary-complex and drug-property innovations — with IP held by PROTAC pioneers, molecular-glue specialists, and a broad degrader field. MAJOR PROTEIN-DEGRADER PATENT HOLDERS: ARVINAS (the PROTAC pioneer, founded on Craig Crews's Yale work): PROTAC platform and many target/E3 combinations, ARV-471 (vepdegestrant, an estrogen-receptor degrader, with Pfizer, in Phase 3 breast cancer), and ARV-110 (androgen-receptor, prostate). KYMERA THERAPEUTICS: the Pegasus degrader platform, IRAK4 and STAT3 degraders, and IRAKIMiD dual degraders (immunology and oncology). C4 THERAPEUTICS: degronimid and BiDAC/MonoDAC platforms (e.g. CFT7455). MONTE ROSA THERAPEUTICS: molecular glue degraders (the QuEEN discovery engine, GSPT1 and other glues). OTHERS: Nurix (DEL-discovered degraders + E3 ligase modulation/inhibition), Foghorn, Plexium, Captor, Cullgen, Frontier Medicines, and Bristol Myers Squibb/Celgene (the CELMoD/IMiD lenalidomide/pomalidomide cereblon molecular glues — the foundational, validated molecular-glue chemotype). PROTAC bifunctional design, molecular glues, and the E3-ligase ligand toolbox are the core TPD patent domains.

Target-ligand innovations; E3-ligase-ligand innovations; linker and ternary-complex innovations; and catalytic and degradation-selectivity innovations represent core PROTAC patent domains — and the complete bifunctional molecule plus its productive ternary complex are the heart of PROTAC IP. PROTAC-CONSTRUCT PATENTS: the bifunctional degrader as composition-of-matter — a ligand that binds the target protein, joined by a linker to a ligand that recruits an E3 ubiquitin ligase, bringing them together so the target is ubiquitinated and destroyed by the proteasome; the specific target-ligand + linker + E3-ligand combination (and the resulting degrader) is the central claim. E3-LIGAND PATENTS: ligands recruiting E3 ligases — cereblon CRBN (the most-used, via IMiD-derived glutarimides) and von Hippel-Lindau VHL (hydroxyproline-based), plus an expanding toolbox (IAP, MDM2, DCAF15/16, KEAP1, RNF114) — new E3-ligase ligands are a high-value, dense patent area. LINKER PATENTS: linker length/composition/rigidity that controls ternary-complex geometry, cooperativity, and degradation efficiency. TERNARY-COMPLEX / CATALYTIC PATENTS: designs maximizing the productive ternary complex (target–degrader–E3) and exploiting PROTAC's catalytic, sub-stoichiometric, event-driven pharmacology (one degrader destroys many target copies), plus degradation selectivity. The complete bifunctional degrader and novel E3-ligase ligands are the highest-value PROTAC IP.

Molecular-glue innovations; E3-ligase-toolbox-expansion innovations; degrader-modality innovations; and drug-property and oral-bioavailability innovations represent additional TPD patent domains — and molecular glues plus drug-like properties are where the field is racing. MOLECULAR-GLUE PATENTS: monovalent small molecules that 'glue' a target protein to an E3 ligase by inducing or stabilizing a protein-protein interaction (creating a neosubstrate) — historically serendipitous (lenalidomide/cereblon → IKZF1/3), now rationally discovered (Monte Rosa QuEEN, screening); molecular glues are smaller and more drug-like than PROTACs, making them a major focus. E3-TOOLBOX PATENTS: discovering and developing ligands for new E3 ligases (the human genome has ~600 E3s; only a handful are drugged) to expand tissue-selective and target-selective degradation — a foundational land grab. MODALITY PATENTS: LYTACs (lysosome-targeting for extracellular/membrane proteins), AUTACs/ATTECs (autophagy-targeting), RNA-degraders (RIBOTACs), antibody-PROTAC conjugates, and reversible/photoswitchable degraders. DRUG-PROPERTY PATENTS: making degraders orally bioavailable despite high molecular weight ('beyond rule of 5' chemistry), formulation, and PK/permeability optimization. Rationally-discovered molecular glues, new E3-ligase ligands, and beyond-rule-of-5 oral degraders are the highest-value, fastest-moving TPD IP.

Protein degrader startup IP strategy must navigate Arvinas's foundational PROTAC estate (Crews/Yale licensed), Celgene/BMS cereblon/IMiD molecular-glue patents (the validated glue chemotype is heavily held), Kymera/C4/Monte Rosa platform patents, the E3-ligase-ligand land grab, and a landscape where the degrader (composition-of-matter) and novel E3 ligands are the durable assets; understand that PROTAC and cereblon-glue concepts are foundationally patented (FTO needed), that the open frontier is new E3 ligases, rationally-designed molecular glues, and beyond-rule-of-5 oral degraders, and that a specific degrader against a target is composition-of-matter like any drug; identify whitespace in novel E3-ligase ligands, molecular glues, tissue-selective degradation, and degrading 'undruggable' targets. PROTEIN-DEGRADER STARTUP IP STRATEGY: THE DEGRADER (COMPOSITION-OF-MATTER) AND NOVEL E3 LIGANDS ARE THE IP: patent the specific bifunctional degrader or molecular glue against a target (a new chemical entity, same 20-year protection as any drug) AND novel E3-ligase ligands; NEW E3 LIGASES ARE A FOUNDATIONAL LAND GRAB — HIGHEST-VALUE: only a few of ~600 human E3 ligases are drugged; ligands for new E3s (enabling tissue/target-selective degradation) are the most valuable, least-consolidated whitespace; MOLECULAR GLUES ARE THE DRUG-LIKE FRONTIER: rationally-discovered monovalent glues are smaller and more oral-friendly than PROTACs — but watch the cereblon/IMiD estate (BMS/Celgene); ORAL BEYOND-RULE-OF-5 CHEMISTRY IS A REAL DIFFERENTIATOR: PROTACs are large; chemistry/formulation enabling oral bioavailability is patentable and commercially decisive; DEGRADE THE UNDRUGGABLE: degraders can hit scaffolding/transcription-factor targets that inhibitors can't (event-driven, catalytic) — a strategic target-selection advantage; WHEN TO PATENT: NOVEL DEGRADER/GLUE/LIGAND WITH MEASURED DEGRADATION: file once a molecule shows measured results (DC50 degradation potency + Dmax + selectivity + ternary-complex cooperativity + oral PK) — measured degradation potency (DC50/Dmax), selectivity, ternary-complex cooperativity, and oral bioavailability are the critical TPD IP metrics; KEY FTO CHECKLIST: Arvinas/Crews PROTAC bifunctional platform; Celgene/BMS lenalidomide/pomalidomide cereblon IMiD molecular glue (foundational); CRBN cereblon (glutarimide) and VHL (hydroxyproline) E3 ligands; novel E3 ligases (IAP/MDM2/DCAF15/KEAP1/RNF114); Kymera Pegasus, C4 degronimid, Monte Rosa QuEEN glue; linker/ternary-complex cooperativity; LYTAC/AUTAC/RIBOTAC modalities; beyond-rule-of-5 oral chemistry; composition-of-matter degrader.